In the Spotlight
New Article Collections! Read recently published, impactful articles related to the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting.
Explore the Best of: Author Profiles. Learn more about the authors behind the AACR’s highly cited articles: who they are, how they chose their career paths, and what excites them most about their work as cancer researchers.
Read the recent blog post, "Recent Advances in Measuring Response to Immune Checkpoint Inhibitors,” highlighting studies published in our Journals: Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research, and Cancer Immunology Research
Read "Plasma Metabolites Predict Response to MEK Inhibition" in MCT's October issue. Using liquid chromatography/mass spectrometry (LC/MS)-based metabolomics and the MEK inhibitor RO4987655, 21 plasma metabolite markers of MEK inhibition in two sensitive BRAF mutant, human melanoma xenograft models were identified. Of these, Ang and colleagues found that on-treatment changes in the concentrations of 15 metabolites significantly predicted objective responses in patients with advanced melanoma treated with RO4987655. In patients with progressive disease, it was demonstrated that propionyl carnitine and amino acid levels increased; while in those patients that responded, phosphatidylcholines and sphingomyelin concentrations decreased. In addition, the pre-treatment levels of seven plasma metabolites (phosphatidylcholines and sphingomyelins) had significant prognostic value. Learn more in the latest issue of MCT.